Home > Healthcare > Pharmaceuticals > Pharma Manufacturing > In Vivo CRO Market

In Vivo CRO Market Share

Report ID: GMI8993
Published Date: Apr 2024
Report Format: PDF

Download Free Sample

In Vivo CRO Market Share

The in vivo CRO industry is characterized by the presence of several key players offering innovative services. The strategic partnerships, mergers, and acquisitions are common strategies employed by players to expand their market presence, enhance their service portfolios, and gain a competitive advantage.

In Vivo CRO Market Companies

Prominent players operating in the in vivo CRO industry include:

Biocytogen
Charles River Laboratories International Inc.
Crown Bioscience
Evotec SE
GemPharmatech Co. Ltd.
IQVIA Inc.
Icon Plc
Labcorp Drug Development
Parexel International Corporation
PsychoGenics Inc.
Taconic Biosciences, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

In vivo CRO market was valued at USD 4.7 billion in 2023 and is set to grow at 7.8% CAGR from 2024 to 2032, driven by the increasing complexity of drug development process.

The bioanalysis & DMPK studies service segment held 40.6% of the market share in 2023 and is set to grow rapidly by 2032, driven by complexity of new drug candidates, including biologics and gene therapies.

North America in vivo CRO market size was USD 2 billion in 2023 and is set to grow at 7.6% CAGR between 2024 – 2032, driven by well-established pharmaceutical and biotechnology industries.

Biocytogen, Charles River Laboratories International Inc. , Crown Bioscience, Evotec SE, GemPharmatech Co. Ltd., IQVIA Inc., Icon Plc, Labcorp Drug Development, Parexel International Corporation among others.